Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233064 · ClinicalTrials.gov registry record · Phase 4
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
A Phase 4 study of Chronic Lung Disease, sponsored by MedImmune.
- Completed
- Registry status
- Phase 4
- Development phase
- 417
- Enrollment target
- 20
- Study locations
NCT00233064: Completed Phase 4 study of Chronic Lung Disease, sponsored by MedImmune.
NCT00233064 is a Phase 4 study of Chronic Lung Disease that has completed, run by MedImmune. The registered enrollment target is 417 participants, above the 311-participant average among 9 other Chronic Lung Disease trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233064, a Phase 4 study of Chronic Lung Disease, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 417 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the rate of anti-palivizumab antibodies (also referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid or lyophilized formulation of palivizumab. This study will compare the number and percentage of subjects with anti-palivizumab antibodies receiving either the liquid or lyophilized formulation of palivizumab.
Primary Outcome
Presence of anti-palivizumab antibodies
Conditions Studied
Interventions
- BIOLOGICAL Lyophilized Palivizumab
- BIOLOGICAL Liquid Palivizumab
Study Locations (20)
California
- Family Medical Center - Foothill Ranch
- Edinger Medical Group - Fountain Valley
- Doctors Medical Group - West Covina
- Convenience Care - West Covina
Alabama
- Birmingham Pediatric Associates - Birmingham
- Clinical Research Consultants - Hoover
- The University of Alabama School of Medicine - Tuscaloosa
Massachusetts
- Boston University Medical Center - Boston
- Pediatric Association of Fall River - Fall River
- Woburn Pediatric Associates - Woburn
Kentucky
- Physicians to Children and Adolescents - Bardstown
- Peak Medical Research LLC - Owensboro
Arkansas
- All for Kids Pediatric Clinic - Little Rock
Connecticut
- Norwich Pediatric Group, P.C. - Norwich
Georgia
- The Allergy Center at Brookstone - Columbus
Michigan
- Michigan Institute of Medicine - Livonia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
What the finished NCT00233064 record still lists
NCT00233064 is an interventional study that assigns participants to a tested intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap, above the 311-participant average among 9 other Chronic Lung Disease trials with a reported enrollment target (34% higher).
The record links to 1 condition, with Chronic Lung Disease appearing as the primary indexed condition, and to 2 interventions - of which Lyophilized Palivizumab is the first listed.
NCT00233064 names 20 study sites across 12 states, led by California, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00233064 about?
NCT00233064 is a clinical study titled "Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)". The purpose of this study is to measure the rate of anti-palivizumab antibodies (also referred to as immune reactivity or immunogenicity) in subjects receiving either the liquid or lyophilized formulation of palivizumab. This study will compare the number and percentage of subjects with anti-paliviz...
What is the current status of trial NCT00233064?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 417 participants. The study started on 2005-10. Estimated completion is 2007-11.
What conditions does trial NCT00233064 study?
This clinical trial studies the following conditions: Chronic Lung Disease.
What interventions are being tested in trial NCT00233064?
The interventions under investigation include: Lyophilized Palivizumab (BIOLOGICAL), Liquid Palivizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00233064?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00233064 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lung Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00233064's enrollment target sits among peer trials
417 3rd of 9 higher than 7 of 9 other Chronic Lung Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lung Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence
RECRUITING · NA
-
Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension
RECRUITING
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
RECRUITING
-
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
RECRUITING
-
Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through Exercise
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia